Newsroom
Spotlight Story
Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape
Read more
Press Releases
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX…
Read More
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES)…
Read More
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual…
Read More
UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F…
Read More
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver…
Read More
UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia…
Read MoreUCB Stories
Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented
Read More
Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape
Read More
Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions
Read More
Closing gaps in HS care through community engagement and scientific innovation
Read More
A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology
Read More
